Literature DB >> 108220

Comparative antibacterial activity of azlocillin, mezlocillin, carbenicillin and ticarcillin and relative stability to beta-lactamases of pseudomonas aeruginosa and klebsiella aerogenes.

M J Basker, R A Edmondson, R Sutherland.   

Abstract

The antibacterial activities of two ureidopenicillins, azlocillin and mezlocillin, were compared with those of the alpha-carboxypenicillins, carbenicillin and ticarcillin, against a large number of gram-positive and gram-negative bacteria. All four penicillins were active against a wide range of bacteria including Pseudomonas aeruginosa, but there were differences in the antibacterial spectra and in the antibacterial effects demonstrated by the two classes of penicillins. In particular, the minimum inhibitory concentrations of azlocillin and mezlocillin against Klebsiella aerogenes and against P. aeruginosa were greatly influenced by the size of bacterial inoculum tested whereas there was no significant inoculum effect with carbenicillin and ticarcillin. In stability tests, the ureidopenicillins were inactivated rapidly by the beta-lactamases of K. aerogenes and P. aeruginosa whereas the alpha-carboxypenicillins were stable. It seems probable that the inoculum effect seen with azlocillin and mezlocillin in antibacterial tests with K. aerogenes and P. aeruginosa is associated with the instability of the compounds to the beta-lactamases of these bacteria.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 108220     DOI: 10.1007/bf01641616

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  15 in total

1.  Antibacterial activity of apalcillin (PC-904) against gram-negative bacilli, especially ampicillin-, carbenicillin-, and gentamicin-resistant clinical isolates.

Authors:  H Noguchi; M Kubo; S Kurashige; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

2.  [Azlocillin--a new penicillin against Pseudomonas aeruginosa and other gram-negative bacteria].

Authors:  H B König; K G Metzger; R P Mürmann; H A Offe; P Schacht; W Schröck
Journal:  Infection       Date:  1977       Impact factor: 3.553

3.  Mezlocillin: in vitro studies of a new broad-spectrum penicillin.

Authors:  G P Bodey; T Pan
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

4.  Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins.

Authors:  R Wise; A P Gillett; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

5.  Azlocillin: in vitro studies of a new semisynthetic penicillin.

Authors:  D Stewart; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

6.  Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

7.  -carboxy-3-thienylmethylpenicillin (BRL 2288), a new semisynthetic penicillin: in vitro evaluation.

Authors:  R Sutherland; J Burnett; G N Rolinson
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

8.  Azlocillin and mezlocillin: new ureido penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

9.  BL-P1654: a bacteriostatic penicillin?

Authors:  C C Sanders; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

10.  Factors affecting the synthesis of ampicillin and hydroxypenicillins by the cell-bound penicillin acylase of Escherichia coli.

Authors:  M Cole
Journal:  Biochem J       Date:  1969-12       Impact factor: 3.857

View more
  16 in total

1.  Inoculum effect of β-lactam antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

Review 2.  [Fifty years of penicillins. A review of structure-effect relationships of beta-lactamase antibiotics and their microbiological and clinical relevance (author's transl)].

Authors:  A Dalhoff
Journal:  Infection       Date:  1979       Impact factor: 3.553

3.  In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum.

Authors:  D A Conrad; R K Scribner; A H Weber; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

4.  [Therapy with cefotaxime-cefotaxime/ticarcillin for bronchopulmonary infections in patients under intensive care. (author's transl)].

Authors:  C D Schwigon
Journal:  Infection       Date:  1982       Impact factor: 3.553

5.  Susceptibility of gram-negative bacteria and Staphylococcus aureus to combinations of ticarcillin and clavulanic acid.

Authors:  P Casey; M Glauser
Journal:  Eur J Clin Microbiol       Date:  1983-12       Impact factor: 3.267

6.  [Azlocillin--a new anti-pseudomonas penicillin. A review of the literature and pharmacokinetic studies].

Authors:  Z Modr; K Dvorácek; I Janků; V Krebs
Journal:  Infection       Date:  1982       Impact factor: 3.553

7.  Comparative in vitro antibacterial activity of seven semi-synthetic penicillins against aerobic gram-negative bacteria and enterococci.

Authors:  A Thabaut; J L Durosoir; P Saliou
Journal:  Infection       Date:  1982       Impact factor: 3.553

8.  Statistical comparison of the antibacterial activities of broad-spectrum penicillins against gram-negative bacilli.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

9.  Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects.

Authors:  H Kobayashi; Y Takemura; T Ohnuma
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 10.  Ticarcillin: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.